このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Fortress Biotech 将来の成長

Future 基準チェック /26

Fortress Biotechの収益は年間7%で減少すると予測されていますが、年間収益は年間25.4%で増加すると予想されています。EPS は年間22.2%で増加すると予想されています。

主要情報

-7.0%

収益成長率

22.2%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	25.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 May 2024

今後の成長に関する最新情報

Recent updates

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

Fortress Biotech founded Cyprium's CUTX-101 nabs accelerated review for copper metabolism disorder

Dec 15

Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?

Dec 15

Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?

Nov 19

Fortress Biotech EPS misses by $0.02, misses on revenue

Nov 09

業績と収益の成長予測

NasdaqCM:FBIO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	168	-75	N/A	N/A	2
12/31/2025	126	-76	N/A	N/A	3
12/31/2024	74	-89	N/A	N/A	3
3/31/2024	85	-63	-113	-110	N/A
12/31/2023	85	-69	-136	-128	N/A
9/30/2023	62	-78	-150	-141	N/A
6/30/2023	63	-96	-176	-168	N/A
3/31/2023	64	-100	-182	-176	N/A
12/31/2022	76	-95	-202	-179	N/A
9/30/2022	78	-97	-196	-170	N/A
6/30/2022	82	-93	-181	-149	N/A
3/31/2022	81	-74	-179	-142	N/A
12/31/2021	69	-65	-133	-117	N/A
9/30/2021	64	-38	-113	-98	N/A
6/30/2021	53	-33	-110	-101	N/A
3/31/2021	44	-43	-89	-83	N/A
12/31/2020	46	-47	-91	-84	N/A
9/30/2020	43	-57	-99	-88	N/A
6/30/2020	43	-54	-92	-81	N/A
3/31/2020	43	-54	-102	-92	N/A
12/31/2019	37	-40	-104	-95	N/A
9/30/2019	34	-45	-98	-92	N/A
6/30/2019	30	-51	-106	-101	N/A
3/31/2019	27	-53	-105	-96	N/A
12/31/2018	27	-73	-108	-99	N/A
9/30/2018	-107	-61	-107	-98	N/A
6/30/2018	-65	-69	-105	-98	N/A
3/31/2018	-22	-72	-102	-98	N/A
12/31/2017	17	-65	N/A	-81	N/A
9/30/2017	155	-74	N/A	-78	N/A
6/30/2017	109	-60	N/A	-62	N/A
3/31/2017	61	-55	N/A	-46	N/A
12/31/2016	16	-55	N/A	-46	N/A
9/30/2016	4	-50	N/A	-35	N/A
6/30/2016	3	-55	N/A	-31	N/A
3/31/2016	1	-49	N/A	-30	N/A
12/31/2015	1	-48	N/A	-20	N/A
9/30/2015	1	-40	N/A	-17	N/A
6/30/2015	1	-27	N/A	-14	N/A
3/31/2015	1	-25	N/A	-12	N/A
12/31/2014	N/A	-20	N/A	-16	N/A
9/30/2014	N/A	-26	N/A	-20	N/A
6/30/2014	N/A	-30	N/A	-24	N/A
3/31/2014	N/A	-36	N/A	-28	N/A
12/31/2013	N/A	-37	N/A	-30	N/A

アナリストによる今後の成長予測

収入対貯蓄率: FBIO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: FBIO今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: FBIO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: FBIOの収益 ( 25.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: FBIOの収益 ( 25.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: FBIOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Fortress Biotech 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 93%, revenue upgraded

No longer forecast to breakeven

Price target increased by 27% to US$67.50

Price target decreased by 14% to US$50.00

Forecast to breakeven in 2024

Price target decreased by 8.1% to US$3.55

Recent updates

Consensus EPS estimates fall by 93%, revenue upgraded

New major risk - Negative shareholders equity

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

New major risk - Revenue and earnings growth

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Executive Chairman recently bought US$119k worth of stock

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Price target increased by 27% to US$67.50

Price target decreased by 14% to US$50.00

Forecast to breakeven in 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Fortress Biotech, Inc. has completed a Composite Units Offering.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

New major risk - Share price stability

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Price target decreased by 8.1% to US$3.55

Consensus revenue estimates fall by 20%

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2025

Consensus revenue estimates increase by 36%

Price target decreased by 13% to US$4.34

Consensus revenue estimates fall by 40%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Receives Second 180-Calendar Day Grace Period from Nasdaq to Regain Compliance with the Nasdaq Listing Rule 5550(a)(2)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 16% to US$5.10

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $13.896816 million.

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Price target decreased to US$5.92

Executive Chairman recently bought US$68k worth of stock

No longer forecast to breakeven

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insufficient new directors

Fortress Biotech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Executive Chairman recently bought US$70k worth of stock

Urica Therapeutics, Inc Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Consensus revenue estimates fall by 13%

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Fortress Biotech, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Fortress Biotech Inc. Appoints David Jin as Chief Financial Officer

David Jin is the new finance chief of Fortress Biotech

Price target decreased to US$6.10

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 2000 Dynamic Index

Fortress Biotech, Inc.'s Subsidiary UR-1 Therapeutics, Inc. Doses First Patient in a Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Fortress Biotech, Inc. to Report Q1, 2022 Results on May 10, 2022

Fortress Biotech, Inc., Annual General Meeting, Jun 21, 2022

Price target decreased to US$6.60

Forecast breakeven date pushed back to 2024

Insufficient new directors

Consensus revenue estimates fall by 19%

Price target decreased to US$6.60

Forecast breakeven date pushed back to 2024

Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Fortress Biotech, Inc. Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV